



**Dr. Kadir ÇALIŞKAN**

Dr. Kadir Çalışkan was born in 1967 in Mucur, Kırşehir, and immigrated to the Netherlands with his family in 1978. He completed his medical education at the University of Amsterdam in 1994, gaining extensive clinical experience in cardiology, internal medicine, and pulmonology thereafter. Upon completing his residency in cardiology at the Erasmus MC University Medical Centre in Rotterdam, he began his tenure as a consultant cardiologist in the Department of Cardiology at the same institution in 2004. Specializing in advanced heart failure, cardiomyopathies, heart transplantation, and mechanical circulatory support systems from the early stages of his career, Dr. Çalışkan has gained national and international recognition, particularly for his pioneering work on Noncompaction Cardiomyopathy (NCCM). In 2005, he established the first NCCM outpatient clinic in the Netherlands; today, this centre serves over 300 patients and has become the national point of reference. His published research on sarcomere gene mutations, rigid body rotation, cardiogenetic subtypes, and clinical outcomes regarding NCCM stands among the most significant resources in the literature. His doctoral thesis, titled “Clinical Features of Noncompaction Cardiomyopathy” (2012), contributed significantly to the understanding of NCCM clinical phenotypes, and he served as co-editor of the first NCCM monograph published by Springer in 2019. To date, Dr. Çalışkan has contributed to more than 200 peer-reviewed articles and book chapters, producing high-impact scientific publications on heart transplantation and mechanical circulatory support systems. Dr. Çalışkan has undertaken numerous leadership roles within Erasmus MC, serving as the Clinical Director of the Medium Care Cardiology Unit (2009–2013) and the Clinical Director of the Heart Failure and Heart Transplantation Unit (2013–2020). Furthermore, between 2013 and 2025, he served as the coordinator for cardiology residency training in advanced heart failure, heart transplantation, and mechanical support devices. Through his role as an educator, his clinical vision, and his researcher identity, he has made substantial contributions to the development of Erasmus MC in these fields. Active in European and international platforms, Dr. Çalışkan represented the Netherlands on the Eurotransplant Thoracic Advisory Board (2015–2020) and served on the board of the European Registry for Patients with Mechanical Circulatory Support

(EUROMACS) from 2014 to 2022. He currently serves on the Editorial Advisory Board of the Journal of Heart and Lung Transplantation and remains a member of the EUROMACS Scientific Board. In recent years, he has focused his research on the development of advanced heart failure treatments, the optimization of mechanical circulatory support devices, the improvement of heart transplant outcomes, and the in-depth examination of cardiomyopathy phenotypes. He is also the principal investigator for multicentre studies such as the Rijnmond Heart Failure & Cardiomyopathy Registry, the EuroEchoVAD Study, and the EuroNCCM Registry. In 2023, Dr. Çalışkan secured a €2.5 million European Innovation Council (EIC) Transition Grant for a joint project with Koç University (Istanbul) and the Royal College of Surgeons in Ireland (Dublin), leading the development of a right ventricular assist device. With his clinical excellence, research productivity, and innovative approach, he is regarded as one of Europe's leading experts in heart failure and transplantation.